Parkinson's Disease最新文献

{"title":"Substantia Nigra Echogenicity Signal Correlated with Clinical Features in Patients with Parkinson's Disease in Xinjiang.","authors":"Rurui Wei,&nbsp;Yan Zhang,&nbsp;Peishan Li,&nbsp;Zeheng Xu,&nbsp;La Zhang,&nbsp;Yan He,&nbsp;Qinfen Wu,&nbsp;Youcai Shi,&nbsp;Yang Yuan,&nbsp;Abudula Aisha","doi":"10.1155/2023/8867546","DOIUrl":"https://doi.org/10.1155/2023/8867546","url":null,"abstract":"<p><strong>Background: </strong>Transcranial sonography (TCS) is a noninvasive test that can reveal structural changes in the substantia nigra (SN) in Parkinson's disease (PD). The purpose of this study was to investigate the relationship between SN signatures and clinical features in PD patients in a multiethnic region of China.</p><p><strong>Methods: </strong>A total of 147 patients with PD were included in the study, and all of whom had underwent a TCS examination. Clinical information was collected from PD patients, and motor and nonmotor symptoms were assessed using assessment scales.</p><p><strong>Results: </strong>There were differences in the substantia nigra hyperechogenicity (SNH) area between age of onset, visual hallucinations (VH), and UPDRS3.0 II scores (<i>P</i> < 0.05), patients with late onset PD had a greater SNH area than early onset (0.326 ± 0.352 vs. 0.171 ± 0.194), and PD patients presenting with VH had a greater SNH area than those without hallucinations (0.508 ± 0.670 vs. 0.278 ± 0.659), and further multifactorial analysis showed that a high SNH area was an independent risk factor for development of VH. The area under the ROC curve for predicting VH from the SNH area in PD patients was 0.609 (95% CI: 0.444-0.774). There was a positive correlation between the SNH area and UPDRS3.0-II scores, but further multifactorial analysis showed that SNH was not an independent predictor of the UPDRS3.0-II score.</p><p><strong>Conclusion: </strong>A high SNH area is an independent risk factor for development of VH, there is a positive correlation between the SNH area and UPDRS3.0 II score, and TCS has guiding significance in predicting clinical VH symptoms and activities of daily living in PD patients.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"8867546"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250089/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9611791","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Relationship between Visual-Evoked Potential and Optic Coherence Tomography and Clinical Findings in Parkinson Patients.","authors":"Zeynep Tuncer,&nbsp;Gamze Dereli Can,&nbsp;Hava Dönmez Keklikoğlu,&nbsp;Fatma Ayşen Eren,&nbsp;Fatma Yülek,&nbsp;Orhan Deniz","doi":"10.1155/2023/7739944","DOIUrl":"https://doi.org/10.1155/2023/7739944","url":null,"abstract":"<p><strong>Background: </strong>In Parkinson's disease (PD), dopamine deficiency is present not only in the nigrostriatal pathway but also in the retinal and visual pathways. Optic coherence tomography (OCT) can be used as morphological evidence of visual influence from early nonmotor symptoms. The aim of this study was to investigate the relationship of OCT and visual evoked potentials (VEPs) of eyes with the severity of clinical findings and ocular findings in PD.</p><p><strong>Methods: </strong>A group of 42 patients diagnosed with idiopathic PD and a control group of 29 people between the ages of 45-85 were included in our study. VEP was recorded in the patient and control groups. OCT measurement was made with the Optovue spectral-domain device. Foveal thickness and macular volume were measured in the foveal region and in the parafoveal and perifoveal regions in the temporal, superior, nasal, and inferior quadrants. RNFL (retinal nerve fiber layer) was measured in temporal, superior, nasal, and inferior quadrants. Ganglion cell complex (GCC) was evaluated in the superior and inferior quadrants. Using the UPDRS clinical scale, the relationship between measurements and the differences between the control group and the patient group were evaluated.</p><p><strong>Results: </strong>Among the OCT values in our study, foveal, parafoveal, perifoveal thickness, macular volume, RNFL, and GCC measurements were performed for the right and left eyes, and no difference was found between the patient group and the control group. There was no difference in VEP amplitude and latency values between the patient and control groups. The relationships between UPDRS and modified Hoehn Yahr staging and OCT and VEP measurements in the patient revealed no correlation.</p><p><strong>Conclusions: </strong>Studies on whether OCT measurements can functionally be a marker or which segments are more valuable for disease progression in patients with PD are needed. Visual dysfunction in PD cannot be attributed only to retinal pathology; however, the retina may provide monitoring of the status of dopaminergic neurodegeneration and axonal loss in PD.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"7739944"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9981293/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10847926","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Lived Experience of Caregiving and Perception of Service Provision among Family-Caregivers of People with Late-Stage Parkinson's: A Qualitative Study.","authors":"Joy Read,&nbsp;Sarah Cable,&nbsp;Gergely Bartl,&nbsp;Charlotte Löfqvist,&nbsp;Susanne Iwarsson,&nbsp;Anette Schrag","doi":"10.1155/2023/4483517","DOIUrl":"https://doi.org/10.1155/2023/4483517","url":null,"abstract":"<p><strong>Background: </strong>The complex nature of late-stage Parkinson's requires multiagency support and leads to an increased burden on family members who assume a multiplicity of responsibilities. The aim of this study is to further understand the lived experiences of family-caregivers and their perception of, and satisfaction with, service provision.</p><p><strong>Methods: </strong>This qualitative substudy was a part of the European multicentre Care of Late-Stage Parkinsonism (CLaSP) project. Purposive sampling resulted in a sample of eleven family-caregivers of people with late-stage Parkinson's, who were interviewed using semistructured open-ended questions. Thematic analysis followed. <i>Findings</i>. Three overarching themes were developed from the data: ensuring continuous support is vital to providing care at home, perceiving unmet service provision needs, and advocating and co-ordinating all aspects of care take their toll. These themes include not only experience of services that caregivers find supportive in order to deliver care but also of disjointed care between multiple agencies, a perceived lack of Parkinson's expertise, and there was a lack of anticipatory future planning. The constancy and scope of the family-caregiver role is described, including the need to project manage multiple aspects of care with multiple agencies, to be an advocate, and to assume new roles such as managing finances. Multiple losses were reported, which in part was mitigated by gaining expertise through information and support from professionals and organised and informal support.</p><p><strong>Conclusion: </strong>The intricacies and consequences of the family-caregivers' role and their experience of service provision indicate the need to acknowledge and consider their role and needs, fully involve them in consultations and provide information and joined-up support to improve their well-being, and ensure their continuous significant contribution to the ongoing care of the person with Parkinson's.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":"2023 ","pages":"4483517"},"PeriodicalIF":3.2,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9918353/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9259584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of Gastrointestinal Symptoms on Health-Related Quality of Life in an Australian Parkinson's Disease Cohort.","authors":"Jade E Kenna,&nbsp;Megan C Bakeberg,&nbsp;Maddison Y Abonnel,&nbsp;Frank L Mastaglia,&nbsp;Ryan S Anderton","doi":"10.1155/2022/4053665","DOIUrl":"https://doi.org/10.1155/2022/4053665","url":null,"abstract":"<p><strong>Background: </strong>Gastrointestinal symptoms (GIS) in people with Parkinson's disease (PwP) are often underreported and may remain untreated. Constipation is a common nonmotor symptom that can adversely affect health-related quality of life (QoL); however, the impact of other GIS has not been adequately investigated.</p><p><strong>Objectives: </strong>To investigate the relationship between QoL and constipation using the Bristol Stool Chart, bowel movement frequency, and a perceived constipation measure; and to explore the relationship between QoL and other GIS in an Australian PD cohort.</p><p><strong>Methods: </strong>The impact of constipation and other GIS on QoL, as measured using the PDQ-39 scale, was assessed in a cohort of 144 (89 males, 55 females) clinic-attending PwP. Constipation was assessed using the Bristol Stool Chart as well as a composite constipation measure, and the Gastrointestinal Symptom Rating Scale (GSRS) was used to rate other GIS. Covariate corrected linear regression models were utilised to determine significant associations between GIS and QoL scores.</p><p><strong>Results: </strong>Individual and combined constipation measures were significantly associated with poorer QoL (<i>p</i>=0.032 and <i>p</i>=0.002, respectively). Analysis of GSRS symptom domains showed that in addition to symptoms of gastrointestinal hypomotility, a number of other symptoms such as increased eructation and increased flatus were also associated with poorer QoL.</p><p><strong>Conclusions: </strong>The findings point to the importance of GIS as contributor to health-related QoL in PwP. A better understanding of the relationship between GIS and QoL will help facilitate the development of more effective screening and treatment programs to improve symptom management and QoL for PwP.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":" ","pages":"4053665"},"PeriodicalIF":3.2,"publicationDate":"2022-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9718626/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35253567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce <i>α</i>-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model.","authors":"Lingyu Zhang,&nbsp;Chun Li,&nbsp;Zijuan Zhang,&nbsp;Zhenqiang Zhang,&nbsp;Qian-Qian Jin,&nbsp;Lin Li,&nbsp;Christian Hölscher","doi":"10.1155/2022/1428817","DOIUrl":"https://doi.org/10.1155/2022/1428817","url":null,"abstract":"<p><p>Insulin desensitization has been observed in the brains of patients with Parkinson's disease (PD), which is a progressive neurodegenerative disorder for which there is no cure. Semaglutide is a novel long-actingglucagon-likepeptide-1 (GLP-1) receptor agonist that is on the market as a treatment for type 2 diabetes. It is in a phase II clinical trial in patients with PD. Two previous phase II trials in PD patients showed good effects with the older GLP-1 receptor agonists, exendin-4 and liraglutide. We have developed a dual GLP-1/GIP receptor agonist (DA5-CH) that can cross the blood-brain barrier (BBB) at a higher rate than semaglutide. We tested semaglutide and DA5-CH in the 6-OHDA-lesion rat model of PD. Treatment was semaglutide or DA5-CH (25 nmol/kg, i.p.) daily for 30 days postlesion. Both drugs reduced the apomorphine-induced rotational behavior and alleviated dopamine depletion and the inflammation response in the lesioned striatum as shown in reduced IL-1<i>β</i> and TNF-<i>α</i> levels, with DA5-CH being more effective. In addition, both drugs protected dopaminergic neurons and increased TH expression in the substantia nigra. Furthermore, the level of monomer and aggregated <i>α</i>-synuclein was reduced by the drugs, and insulin resistance as shown in reduced pIRS-1^ser312 phosphorylation was also attenuated after drug treatment, with DA5-CH being more effective. Therefore, while semaglutide showed good effects in this PD model, DA5-CH was superior and may be a better therapeutic drug for neurodegenerative disorders such as PD than GLP-1 receptor agonists that do not easily cross the BBB.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":" ","pages":"1428817"},"PeriodicalIF":3.2,"publicationDate":"2022-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9678466/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40507983","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Determination of the Unilaterally Damaged Region May Depend on the Asymmetry of Carotid Blood Flow Velocity in Hemiparkinsonian Monkey: A Pilot Study.","authors":"Jincheol Seo,&nbsp;Kyung Seob Lim,&nbsp;Chang-Yeop Jeon,&nbsp;SeungHo Baek,&nbsp;Hyeon-Gu Yeo,&nbsp;Won Seok Choi,&nbsp;Sung-Hyun Park,&nbsp;Kang Jin Jeong,&nbsp;Jinyoung Won,&nbsp;Keonwoo Kim,&nbsp;Junghyung Park,&nbsp;Jiyeon Cho,&nbsp;Jung Bae Seong,&nbsp;Minji Kim,&nbsp;Yu Gyeong Kim,&nbsp;Jae-Won Huh,&nbsp;Samhwan Kim,&nbsp;Yong Hoon Lim,&nbsp;Hyung Woo Park,&nbsp;Hye Min Tak,&nbsp;Man Seong Heo,&nbsp;Ji-Woong Choi,&nbsp;Sun Ha Paek,&nbsp;Youngjeon Lee","doi":"10.1155/2022/4382145","DOIUrl":"https://doi.org/10.1155/2022/4382145","url":null,"abstract":"<p><p>The hemiparkinsonian nonhuman primate model induced by unilateral injection of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) into the carotid artery is used to study Parkinson's disease. However, there have been no studies that the contralateral distribution of MPTP via the cerebral collateral circulation is provided by both the circle of Willis (CoW) and connections of the carotid artery. To investigate whether MPTP-induced unilaterally damaged regions were determined by asymmetrical cerebral blood flow, the differential asymmetric damage of striatal subregions, and examined structural asymmetries in a circle of Willis, and blood flow velocity of the common carotid artery were observed in three monkeys that were infused with MPTP through the left internal carotid artery. Lower flow velocity in the ipsilateral common carotid artery and a higher ratio of ipsilateral middle cerebral artery diameter to anterior cerebral artery diameter resulted in unilateral damage. Additionally, the unilateral damaged monkey observed the apomorphine-induced contralateral rotation behavior and the temporary increase of plasma RANTES. Contrastively, higher flow velocity in the ipsilateral common carotid artery was observed in the bilateral damaged monkey. It is suggested that asymmetry of blood flow velocity and structural asymmetry of the circle of Willis should be taken into consideration when establishing more efficient hemiparkinsonian nonhuman primate models.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":" ","pages":"4382145"},"PeriodicalIF":3.2,"publicationDate":"2022-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9668443/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40477361","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Resistance Training Combined with Balance or Gait Training for Patients with Parkinson's Disease: A Randomized Controlled Pilot Study.","authors":"Johanna Theresia Biebl,&nbsp;Monica Azqueta-Gavaldon,&nbsp;Cornelia Wania,&nbsp;Olena Zettl,&nbsp;Matthias Woiczinski,&nbsp;Leandra Bauer,&nbsp;Claudia Storz,&nbsp;Kai Bötzel,&nbsp;Eduard Kraft","doi":"10.1155/2022/9574516","DOIUrl":"https://doi.org/10.1155/2022/9574516","url":null,"abstract":"<p><strong>Background: </strong>Gait and balance disorders in patients with idiopathic Parkinson's disease (PD) lead to major mobility limitations. To counteract this, physical therapy such as gait, balance, or resistance training is applied. Integrative training methods, which combine these elements, could be particularly effective.</p><p><strong>Objective: </strong>The objective of this study is to evaluate and compare the effects of two integrative interventions on gait and balance of patients with PD.</p><p><strong>Methods: </strong>Twenty-six patients with PD received either resistance training in combination with gait training (gait resistance training, GRT) or resistance training in combination with balance training (stability resistance training, SRT) for six weeks. Gait and balance outcome parameters were assessed before, immediately after, and six weeks after the interventions. The primary outcome parameters were the functional reach test to evaluate balance and stride length to evaluate gait. Secondary outcomes included further gait analysis parameters, knee extension strength, the timed up and go test, and the six-minute walk test.</p><p><strong>Results: </strong>The functional reach test results were significantly better after the intervention in both groups. Stride length increased significantly only in the GRT group. Several further gait parameters and the six-minute walk test improved in the GRT group, and the increase in gait speed was significantly higher than in the SRT group. The SRT group performed better after the intervention regarding the timed up and go test and knee extension strength, the latter being significantly more improved than in the SRT group. At six-week follow-up, the improvement in functional reach was maintained in the SRT group.</p><p><strong>Conclusions: </strong>Integrative therapies, combining gait or balance training with resistance training, have specific positive effects in PD rehabilitation. More pronounced effects on gait parameters are achieved by GRT, while SRT has more impact on balance. Thus, the combination of both training methods might be particularly efficient in improving the mobility of PD patients.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":" ","pages":"9574516"},"PeriodicalIF":3.2,"publicationDate":"2022-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9568326/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33543061","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Apathy following Bilateral Deep Brain Stimulation of Subthalamic Nucleus and Globus Pallidus Internus in Parkinson's Disease: A Meta-Analysis.","authors":"Song Zhang,&nbsp;Shumei Zi,&nbsp;Sihuai Xiong,&nbsp;Heng Peng,&nbsp;Kejia Hu,&nbsp;Hua He","doi":"10.1155/2022/4204564","DOIUrl":"https://doi.org/10.1155/2022/4204564","url":null,"abstract":"<p><p>Parkinson's disease (PD) is a progressive neurodegenerative disorder typically manifested by its motor symptoms. In addition, PD patients also suffer from many nonmotor symptoms (NMSs), such as apathy. Bilateral deep brain stimulation (DBS) of the subthalamic nucleus (STN) and the globus pallidus internus (GPi) are recommended as therapeutic interventions for PD, given their pronounced benefit in reducing troublesome dyskinesia. Apathy, a mood disorder recognized as a NMS of PD, has a negative impact on the prognosis of PD patients. However, the effect of STN-DBS and GPi-DBS on apathy is controversial. In the current meta-analysis, we analyzed apathy following bilateral STN-DBS and GPi-DBS in PD patients. Relevant literature was retrieved from public databases, including PubMed, Cochrane Library, and Embase. Studies were included in our analysis based on the following criterion: such studies should report apathy scores presurgery and postsurgery determined by using the Starkstein Apathy Scale or Apathy Evaluation Scale in patients receiving STN or GPi-DBS with at least three months of follow-up. Upon applying this strict criterion, a total of 13 out of 302 studies were included in our study. A mean difference (MD) and 95% confidence interval (CI) were calculated to show the change in apathy scores. We found a statistically significant difference between the presurgery and postsurgery scores in patients receiving STN-DBS (MD = 2.59, 95% CI = 2.23-2.96, <i>P</i> < 0.00001), but not in patients receiving GPi-DBS (MD = 0.32, 95% CI = -2.78-3.41, <i>P</i>=0.84). STN-DBS may worsen the condition of apathy, which may result from the reduction of dopaminergic medication. In conclusion, STN-DBS seems to relatively worsen the condition of apathy compared to GPi-DBS. Further studies should focus on the mechanisms of postoperatively apathy and the degree of apathy in STN-DBS versus GPi-DBS.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":" ","pages":"4204564"},"PeriodicalIF":3.2,"publicationDate":"2022-10-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9550510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33504014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Like a Wave in Its Variable Shape, Breadth, and Depth: A Qualitative Interview Study of Experiences of Daytime Sleepiness in People with Parkinson's Disease.","authors":"Arja Höglund,&nbsp;Peter Hagell,&nbsp;Ulrika Östlund,&nbsp;Sten Fredrikson,&nbsp;Christina Sandlund","doi":"10.1155/2022/9980177","DOIUrl":"https://doi.org/10.1155/2022/9980177","url":null,"abstract":"<p><strong>Introduction: </strong>Daytime sleepiness is a common nonmotor symptom in Parkinson's disease (PD) which is associated with decreased quality of life and perceived health. However, experiences of daytime sleepiness in people with PD have not been explored. The aim of this qualitative study was to explore experiences of daytime sleepiness in people with PD.</p><p><strong>Materials and methods: </strong>Five women and seven men (42-82 years) with PD for 1.5 to 21 years and excessive daytime sleepiness (i.e., a score of >10 on the Epworth Sleepiness Scale) participated in the study. Data were collected through individual, semistructured, face-to-face interviews and analyzed with qualitative content analysis.</p><p><strong>Results: </strong>Three themes of the experience of daytime sleepiness were revealed: (1) <i>not an isolated phenomenon,</i> (2) <i>something to struggle against or accept</i>, and (3) <i>something beyond sleepiness. Conclusion</i>. Daytime sleepiness is a complex nonmotor symptom in PD which manifests itself in several ways. Some experiences are similar, for instance, the attribution of daytime sleepiness to PD and its medical treatment. Differences depend on how sleepiness manifests itself, affects the person, and impacts daily life, as well as whether it causes feelings of embarrassment. Some participants needed to struggle against daytime sleepiness most of the time, and others had found a way to handle it, for example, with physical activity. However, sleepiness may also be used to benefit the person, for example, if they allow themselves to take a power nap to regain energy. The health care professionals can easily underestimate or misinterpret the prevalence and burden of daytime sleepiness because people with PD may describe daytime sleepiness as tiredness, drowsiness, or feeling exhausted, not as sleepiness.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":" ","pages":"9980177"},"PeriodicalIF":3.2,"publicationDate":"2022-09-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9532101/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"33492860","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"<i>MAO-B</i> Polymorphism Associated with Progression in a Chinese Parkinson's Disease Cohort but Not in the PPMI Cohort.","authors":"Shi-Shuang Cui,&nbsp;Ling-Yu Wu,&nbsp;Gen Li,&nbsp;Juan-Juan Du,&nbsp;Pei Huang,&nbsp;Jin Liu,&nbsp;Yun Ling,&nbsp;Kang Ren,&nbsp;Zhong-Lue Chen,&nbsp;Sheng-Di Chen","doi":"10.1155/2022/3481102","DOIUrl":"https://doi.org/10.1155/2022/3481102","url":null,"abstract":"<p><strong>Introduction: </strong>Genetic factors play an important role in Parkinson's disease (PD) risk. However, the genetic contribution to progression in Chinese PD patients has rarely been studied. This study investigated genetic associations with progression based on 30 PD risk loci common in a longitudinal cohort of Chinese PD patients and the Parkinson's Progression Markers Initiative (PPMI) cohort.</p><p><strong>Methods: </strong>PD patients from the true world (TW) Chinese PD longitudinal cohort and the PPMI cohort with demographic information and assessment scales were assessed. A panel containing 30 PD risk single nucleotide polymorphisms was tested. Progression rates of each scale were derived from random-effect slope values of mixed-effects regression models. Progression rates of multiple assessments were combined by using principal component analysis (PCA) to derive scores for composite, motor, and nonmotor progression. The association of genetic polymorphism and separate scales or PCA progression was analysed via linear regression.</p><p><strong>Results: </strong>In the Chinese PD cohort, <i>MAOB</i> rs1799836 was associated with progression based on the Montreal Cognitive Assessment, the top 3 principal components (PCs) of nonmotor PCA and PC1 of the composite PCA. In the PPMI cohort, both MDS-Unified Parkinson's Disease Rating Scale II and motor PC1 progression were associated with <i>RIT2</i> rs12456492. The <i>PARK16</i> haplotype was associated with Geriatric Depression Scale and the State-Trait Anxiety Inventory for Adults progression, and the <i>SNCA</i> haplotype was associated with the Hoehn-Yahr staging progression and motor PC1 progression. Ethnicity-stratified analysis showed that the association between <i>MAOB</i> rs1799836 and PD progression may be specific to Asian or Chinese patients.</p><p><strong>Conclusion: </strong><i>MAOB</i> rs1799836 was associated with the progression of nonmotor symptoms, especially cognitive impairment, and the composite progression of motor and nonmotor symptoms within our Chinese PD cohort. The <i>RIT2</i> rs12456492 and <i>SNCA</i> haplotypes were associated with motor function decline, and the <i>PARK16</i> haplotype was associated with progression in mood in the PPMI cohort.</p>","PeriodicalId":19907,"journal":{"name":"Parkinson's Disease","volume":" ","pages":"3481102"},"PeriodicalIF":3.2,"publicationDate":"2022-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9509281/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"40376853","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}